Dr. Baselga, a prominent figure in the world of cancer research, had helped found the journal and served as an editor for the past eight years. The A.A.C.R., which he formerly led as president, concluded that his omissions were inadvertent and said it would allow Dr. Baselga to continue publishing in its journals. with acknowledged expertise in clinical and translational cancer research,” Dr. Margaret Foti, the group’s chief executive, said in the statement. He also resigned from the boards of the drug maker Bristol-Myers Squibb and Varian Medical Systems, a maker of radiation equipment. Contacted for comment, Dr. Baselga provided the resignation letter he sent to the A.A.C.R.

Source: New York Times December 19, 2018 20:37 UTC